Dentsply, IDMoS in tooth decay detection pact
This article was originally published in Clinica
Dentsply International, the York, Pennsylvania-based dental products manufacturer, has entered a long-term agreement with UK IDMoS to develop and commercialise the latter's patented disease detection and monitoring technology for the dental market.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.